Regeneron Pharmaceuticals (REGN) Interest Expenses (2009 - 2026)

Regeneron Pharmaceuticals' Interest Expenses history runs 18 years deep, the most recent figure standing at $28.3 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 59.89% year-over-year to $28.3 million in Q1 2026; TTM through Mar 2026 was $28.3 million, a 59.89% increase from a year earlier, with the FY2025 full-year figure at $124.0 million, down 80.48% from the prior year.
• Interest Expenses eased to $28.3 million in Q1 2026 per REGN's latest filing, from $64.1 million in the prior quarter.
• Across five years, Interest Expenses topped out at $346.8 million in Q3 2022 and bottomed at $10.2 million in Q2 2025.
• The 5-year median for Interest Expenses is $64.1 million (2025), against an average of $117.9 million.
• Across the five-year window, Interest Expenses surged 2342.25% in 2022 and slumped 88.88% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $17.4 million in 2022, then advanced by 5.75% to $18.4 million in 2023, then soared by 147.28% to $45.5 million in 2024, then soared by 40.88% to $64.1 million in 2025, then plunged by 55.85% to $28.3 million in 2026.
• Per Business Quant, the three latest REGN Interest Expenses figures stand at $28.3 million (Q1 2026), $64.1 million (Q4 2025), and $19.3 million (Q3 2025).